Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Araki, Jun; Okamoto, Isamu; Suto, Ryuichiro; Ichikawa, Yasuko; Sasaki, Ji Ichiro

doi:10.1016/j.lungcan.2004.10.012

Cited by 42 publications

(34 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite this, Araki et al (28) reported the first case of metastatic small cell lung cancer that was successfully treated with gefitinib. In vitro studies by Tanno et al (29) showed that two of five cell lines of lung small cell carcinoma expressed functional EGFR by Western blot and, in addition, showed that gefitinib inhibited phosphorylation of extracellular signal-regulated kinase 1/2 by EGF in cell lines with detectable and undetectable EGFR expression.…”

Section: Discussionmentioning

confidence: 99%

Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

Wang¹,

Zhang²,

MacLennan

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Small cell carcinoma of the urinary bladder is a highly aggressive malignancy with an average life expectancy of only a few months. Epidermal growth factor receptor (EGFR) has been implicated in the pathogenesis and progression of many malignancies. This study was done to investigate EGFR protein expression and gene amplification in a large series of small cell carcinomas of the urinary bladder. Experimental Design: Fifty-two cases of urinary bladder small cell carcinoma were included in this study. Immunostaining for EGFR was done on paraffin-embedded tissue sections, and gene amplification for EGFR was done by fluorescence in situ hybridization. EGFR expression was correlated with clinicopathologic characteristics and clinical outcome. Results: All 52 patients, except 1, had advanced disease (T 2 or above) at presentation. Immunohistochemically, positive EGFR expression was observed in 14 of 52 (27%) cases. No EGFR gene amplification was observed in any of 52 cases by fluorescence in situ hybridization. Forty cases had polysomy and the remaining 12 cases displayed disomy. No correlation between EGFR protein expression and gene amplification was shown. There was no correlation between EGFR expression and clinicopathologic characteristics. Conclusions: EGFR is expressed in a subset of urinary bladder small cell carcinomas; however, expression of EGFR does not correlate with clinicopathologic variables. At the molecular level, EGFR overexpression in small cell carcinoma of the urinary bladder does not seem to be caused by gene amplification. The expression of EGFR raises the possibility that EGFR may be a potential therapeutic target in the treatment of this malignancy.Small cell carcinoma of the urinary bladder is a rare and devastating malignancy with a marked propensity to metastasize (1 -3). Demographically, most patients are male, and most present with the disease during their 6th to 7th decade of life (1, 4). Presenting clinical complaints include hematuria, dysuria, and urinary obstructive symptoms. Occasionally, patients have paraneoplastic syndromes. Coexistence with other types of carcinoma, such as urothelial carcinoma, is quite common. The mortality is very high despite combined treatment modalities, including surgery, radiation therapy, and chemotherapy (5). The molecular pathogenesis of the disease is not fully elucidated and merits additional investigation.A small number of cytogenetic and molecular genetic studies have identified several genetic foci that may harbor tumor suppressor genes and oncogenes that may influence the pathogenesis of small cell carcinoma of the urinary bladder. A cytogenetic study by Atkin et al. (6) showed hypertriploidy and hypertetraploidy, associated with extensive chromosomal rearrangements involving chromosomes 1 to 3, 5 to 7, 9, 11, and 18. Subsequently, Terracciano et al. (7) observed frequent deletions of 10q, 4q, 5q, and 13 q and gains of 8q, 5q, 6p, and 20q, and Leonard et al. (8) showed monosomy 9, homozygous deletion of p16, and trisomy 7.Ep...

show abstract

Section: Discussionmentioning

confidence: 99%

Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

Wang¹,

Zhang²,

MacLennan

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…While further studies enlighten the basis of this transformation, the clinician should keep this event in mind, considering re-biopsy for those patients affected by ADC with rapid progression or unusual behaviour, especially EGFR-mutated ones. The importance of pathological demonstration of a histological shift is due to the mixed response to anti EGFR observed in these patients (27,28), thus recommending SCLC treatment as the main therapeutic option.…”

Section: Histology Shiftmentioning

confidence: 99%

Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration

Tuzi¹,

Bolzacchini²,

Suter³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

As the leading cause of death worldwide, lung cancer has proven itself incurable in the advanced stages. For early stages, endobronchial ultrasounds transbronchial needle aspiration (EBUS-TBNA) is now considered the standard to assess mediastinal lymph node, to define the multimodality therapeutic approach.In recent years, EBUS-TBNA has extended its use also in the metastatic and locally recurrent disease. New molecules, with specific mutations that give resistance to current target therapies, have made re-biopsy at disease progression an important assessment, with therapeutic and clinical implication. Here we present the oncologist's point of view on EBUS-TBNA in the staging process, at recurrence and progression.

show abstract

“…Information about the response on EGFR-TKI in this subtype is lacking. In small cell lung cancer (SCLC) EGFR mutations have not been described, except in case reports on combined SCLC with an adenocarcinoma component, describing some response to EGFR-TKI [164,[170][171][172][173][174][175].…”

Section: Egfr and Histological Typesmentioning

confidence: 99%

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Thunnissen

Kerr

Herth³

et al. 2012

Lung Cancer

202

219

View full text Add to dashboard Cite

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer

Cited by 42 publications

References 6 publications

Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder

Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

Contact Info

Product

Resources

About